Renal denervation for refractory hypertension - technical aspects, complications and radiation exposure.

PURPOSE: To analyze procedural details, complications and radiation exposure in renal denervation (RDN) using the Medtronic Symplicity® device in the treatment of refractory hypertension. MATERIALS AND METHODS: Fifty three consecutive patients underwent RDN. The number of ablations per artery, peri-procedural complications, procedure time (PT), fluoroscopy time (FT), dose-area product (DAP) and procedure-related complications were documented. Additionally, the radiation dose was compared between obese (body mass index ≥ 30 kg/m(2)) and non-obese patients. RESULTS: Bilateral RDN was performed in 50/53 (94 %) cases and with a minimum of 4 ablations per artery in 33/50 (66 %), the mean count being 5.4 (range R: 2 - 13) on the right and 4.3 (R: 1 - 10) on the left. The FT and DAP decreased significantly over the first 12 procedures, reaching a steady state with a median FT of 11.2 min (R: 7.5 - 27) and a median DAP of 4796 cGy × cm(2) (R: 1076 - 21 371), resulting in an effective dose of 15.7 mSv. The median PT was 57 min (R: 40 - 70). Obese patients had a 3.3-fold higher radiation dose (p < 0.001). We observed one severe spasm and one imminent respiratory depression, both resolved without sequelae. CONCLUSION: For an experienced interventionalist, RDN has a short learning curve with a low risk profile. The radiation dose does not exceed that of other renal artery interventions, but is explicitly higher in obese patients, who account for a large portion of patients with refractory hypertension.

Do the cardiovascular risk profile and the degree of arterial wall calcification influence the performance of MDCT angiography of lower extremity arteries?

OBJECTIVES: To retrospectively assess the influence of arterial wall calcifications on the accuracy of run-off computed tomographic angiography (CTA) and to analyse whether cardiovascular risk factors are predictors of compromising calcifications. METHODS: In 200 consecutive patients who underwent run-off CTA, calcifications were assessed in pelvic, thigh and calf arteries using a four-point scale. Fifty-nine patients with digital subtraction angiography (DSA) were assessed by both techniques to estimate a threshold of compromising calcifications, defined as a decrease of sensitivity, specificity, PPV or NPV below the lower 95% confidence interval of overall results. Regression analysis was performed to investigate a potential relationship between compromising calcifications and presence of cardiovascular risk factors, advanced patient age and severe peripheral arterial disease (PAD). RESULTS: The highest Ca(++)-score was chosen as the cut-off for the regression analysis, as a relevant decrease of specificity (0.91; overall: 0.95) above the knee and of sensitivity (0.66; overall: 0.83), specificity (0.65; overall: 0.93), positive predictive value (PPV) and negative predictive value (NPV) below the knee was observed. In the pelvic and thigh arteries, severe PAD (Fontaine Stage >or=III) showed the highest odds ratio for compromising calcifications (2.9), followed by diabetes mellitus (2.4), renal failure (2.1) and smoking (1.7). In the calf, renal failure (12.2) and diabetes mellitus (3.3) were the strongest predictors. CONCLUSIONS: Patients with diabetes and renal failure should be considered as candidates for alternative vessel imaging in order to avoid inconclusive examination results.

Detection of hepatic metastases with low MI real time contrast enhanced sonography and SonoVue.

AIM: SonoVue is the first ultrasound contrast agent which allows repeated continuous examination of the liver in real time. The aim of this study was to compare low mechanical index (MI) real time contrast enhanced ultrasound of the liver, using the contrast agent SonoVue, with conventional B-mode sonography for the detection of hepatic metastases. METHOD: 40 patients with known malignancy and at least one liver lesion on conventional B-mode sonography were included. Conventional B-mode sonography was performed followed by contrast enhanced ultrasound (CEUS) of the liver in the arterial (< 30 sec), portal-venous (40-120 sec) and delayed phase (> 120 sec) after injection of SonoVue. CEUS was performed using contrast specific imaging and low MI (< 0.3). Number, location and size of metastases on baseline and CEUS were compared with CT or MRI (blinded reader). RESULTS: 37 patients had 128 metastases on CT or MRI. Baseline US showed 74 metastases confirmed by reference examination (69%), while CEUS yielded 109 metastases (sensitivity 90%) (p < 0.001). On CEUS, 35 additional metastases not seen on baseline but confirmed by reference imaging were detected in 14 patients (36%). In 8 patients, CEUS showed 13 metastases not seen on reference imaging. CONCLUSION: Detection of hepatic metastases is substantially improved by low MI real time contrast enhanced ultrasound with SonoVue compared to conventional B-mode sonography.

Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.

RATIONALE AND OBJECTIVES: To determine the clinical dose of gadoteridol (ProHance, Bracco-Byk Gulden) to use for the assessment of blood-brain barrier breakdown on low-field magnetic resonance (MR) scanners that corresponds to a standard dose of gadoteridol on high-field MR scanners. METHODS: This prospective study was carried out at four centers. A total of 138 patients with suspected or known brain diseases underwent a routine head scan comprising precontrast T2-weighted turbo spin-echo and T1-weighted spin-echo sequences on a 1.5-T MR scanner. After administration of a standard dose of 0.1 mmol/kg gadoteridol, the T1-weighted scan was repeated after a delay of 15 to 20 minutes. For continuing the examination on a 0.2-T MR scanner (Magnetom OPEN, Siemens), a standard-dose T1 spin-echo sequence was started within 30 to 50 minutes of the first injection. Then two additional T1-weighted low-field sequences were each started 5 minutes after two additional doses of 0.1 mmol/kg gadoteridol. Eighty patients with enhancing lesions underwent an intraindividual comparison. Evaluation of the overall numbers of lesions detected and of lesion size and character was performed on-site as well as off-site by two independent readers. RESULTS: The single-dose, low-field sequence detected significantly fewer enhancing lesions (80/95 lesions; P < 0.05), particularly metastases and infarctions, than did the standard-dose, high-field sequence. No statistically relevant differences (reader 1: P = 1; reader 2: P = 0.8) were found between the double- and triple-dose, low-field sequences and the standard-dose, high-field sequence. Primary brain tumors were detected by all postcontrast sequences irrespective of the dose. CONCLUSIONS: At low field, the clinically equivalent dose to 0.1 mmol/kg gadoteridol at high field is 0.2 mmol/kg. A dose of 0.1 mmol/kg gadoteridol is less effective and cannot be recommended for use on extremely low-field scanners.